Keyword: Imfinzi (durvalumab)
BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.
First rule of ballot stuffing? To avoid raising red flags, don't overdo it. And that’s exactly what 34,035 #FierceMadness votes for Brineura did.
The final showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.
Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.
AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.
BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.
Backed by convincing survival data, AZ’s fifth-to-market immunotherapy Imfinzi just won a breakout FDA approval in certain lung cancer patients.
If you thought 2017 was a game-changer for immuno-oncology, just wait.
If 2016 was the year immuno-oncology first stopped looking invincible, 2017 was the year trial misses became more commonplace.
AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial should do just that, one analyst says.